Revelation Biosciences Q4 net loss widens
Overview
Life sciences firm's Q4 net loss widens yr/yr due to increased operating expenses
Company's cash position improves to $10.7 mln, sufficient to fund operations into Q1 2027
Company advances Gemini program for kidney disease treatment
Outlook
Revelation expects current cash reserves to fund operations into Q1 2027
Company to present Gemini clinical data at conference in March 2026
Result Drivers
OPERATING EXPENSES - Increased to $2.57 mln from $1.75 mln due to more than 50% increase in R&D expenses and a 40% increase in general and administrative expenses
Company press release: ID:nACSs06Y2a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS |
| -$1.65 |
|
Q4 Net Income |
| -$2.51 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Revelation Biosciences Inc is $85.00, about 5,928.4% above its February 25 closing price of $1.41
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
Related Articles
Tesla Steps Up China Market Promotions; Can EV Business Bottom Out and Rebound?
TradingKey - On February 26 local time, Tesla (TSLA) China announced that for orders placed by March 31, select models will be eligible for 7-year ultra-low interest and 5-year zero-interest financing plans, as well as insurance subsidies.
Paramount Offers High Price Again to Bid for Warner Bros., Netflix Acquisition Hits Twists and Turns.
TradingKey - Hollywood media group Warner Bros. (WBD) announced Tuesday that it has received a revised acquisition proposal from Paramount (PSKY), raising the offer from the previous $30 to $31 per share in cash. The Board of Directors stated that this new bid "is likely to constitute a superior proposal" to the current agreement with Netflix and noted that negotiations between the two parties are continuing. The existing deal with Netflix (NFLX) remains in effect, as the Warner Bros. Board has not yet formally designated the Paramount offer as the superior proposal.
Tesla Stock Outlook: Why 2026 Could Be the Year of the Tesla Robotaxi
TradingKey - The concept of autonomous mobility for Tesla(TSLA) has gone from a projection of the far away future to a vital part of its overall long-term growth strategy.
Will Bank of England Still Cut Rates in 2026? Falling Inflation Favors Loose Monetary Policy, Pound Exchange Rate May Struggle to Sustain Strength.
TradingKey - The outlook for the British Pound in 2026 is undoubtedly one of the most significant focal points for investors in the FX market. Following a structural shift in 2025 characterized by a "low start and high finish," GBP/USD successfully broke out of its two-year trading range and stabilized near 1.35 at year-end, laying the foundation for its performance in 2026.
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.
